DEF: Dermata Therapeutics Seeks Shareholder Approval for Reverse Stock Split Amid Nasdaq Delisting Threat and Dilutive Capital Raises

Dermata Therapeutics, Inc. is calling an Annual Meeting of Stockholders to address critical Nasdaq listing compliance issues, including a proposed reverse stock split and the ratification of recent dilutive warrant issuances that raised over $8 million.

Summary

• Dermata Therapeutics, Inc. will hold its Annual Meeting of Stockholders virtually on July 15, 2025, to vote on several key proposals.
• The company is seeking approval for an amendment to its Certificate of Incorporation to effect a reverse stock split with a ratio ranging from one-for-two (1:2) to one-for-thirty (1:30), at the Board's discretion, to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
• A Nasdaq deficiency letter was received on May 14, 2025, due to the stock trading below $1.00 for 30 consecutive business days, with the closing price at $0.79 per share on May 16, 2025, and the company is subject to delisting.
• Shareholders will vote on ratifying the issuance of shares underlying warrants from a January 21, 2025, private placement that generated approximately $2.55 million in gross proceeds (net $2.3 million).
• Shareholders will also vote on ratifying the issuance of shares underlying warrants from a March 27, 2025, warrant inducement that yielded approximately $5.8 million in net proceeds.
• These warrant issuances are subject to Nasdaq Listing Rule 5635(d) approval as they represent 20% or more of the common stock outstanding prior to their respective issuances.
• The Board also seeks approval to elect two Class I directors and ratify Moss Adams LLP (or its successor, Baker Tilly US, LLP) as the independent auditor for 2025.
• As of May 16, 2025, the company had 6,378,118 shares of Common Stock outstanding.

Sentiment

Score: 3

Explanation: The company is facing a severe Nasdaq delisting threat, necessitating a reverse stock split, and has undertaken highly dilutive capital raises to address immediate funding needs. While capital has been secured, the underlying issues of low stock price and continuous dilution indicate significant operational and financial challenges, leading to a negative outlook for existing shareholders.

Positives

• The company successfully raised approximately $2.3 million net proceeds from a private placement in January 2025 and approximately $5.8 million net proceeds from a warrant inducement in March 2025, addressing immediate cash and funding requirements.
• Company insiders, including the CEO and a director, participated in the January 2025 private placement, demonstrating some level of internal confidence.
• The Board is actively addressing the Nasdaq listing deficiency by proposing a reverse stock split and seeking shareholder approval for necessary capital raises.

Negatives

• The company received a Nasdaq deficiency letter on May 14, 2025, indicating non-compliance with the $1.00 minimum bid price requirement, with its stock closing at $0.79 per share on May 16, 2025, and is subject to delisting.
• The necessity of a reverse stock split, especially after a prior one within the last year, indicates persistent low stock price issues and potential underlying business challenges.
• The proposed warrant issuances (Issuance Proposal and Inducement Proposal) will result in significant dilution for existing shareholders, as they involve shares equal to or exceeding 20% of the common stock outstanding prior to each issuance.
• The cancellation of outstanding executive and director stock options for no consideration in February 2024, without replacement, could be a negative signal regarding past equity value.

Risks

• **Delisting Risk**: Failure to approve the reverse stock split or inability to regain and maintain Nasdaq compliance could lead to delisting, adversely affecting liquidity and investor interest.
• **Dilution**: The approval and exercise of warrants from the January 2025 private placement and March 2025 inducement offer will significantly dilute existing shareholders' ownership and voting power.
• **Funding Risk**: If shareholders do not approve the warrant issuances, the company will not receive potential additional proceeds of approximately $2.8 million (from January 2025 warrants) and $13.0 million (from March 2025 warrants), which could jeopardize its ability to fund operations.
• **Market Price Volatility**: There is no assurance that the reverse stock split will increase the stock price proportionally or maintain it above the Nasdaq minimum, and the stock price may continue to decline due to other factors.
• **Anti-Takeover Effect**: The effective increase in authorized but unissued shares resulting from the reverse stock split could be used to deter potential takeovers, potentially limiting opportunities for shareholders to sell at a premium.
• **Increased Transaction Costs**: A reverse stock split may result in more stockholders owning 'odd lots' (less than 100 shares), which can incur higher transaction costs per share.

Future Outlook

The company's future outlook is heavily dependent on regaining Nasdaq compliance through a proposed reverse stock split and securing additional capital from the exercise of recently issued warrants. The Board intends to use the increased authorized shares for future financings, employee benefit programs, and other corporate activities. However, the success of these measures and their impact on the stock price and liquidity remain uncertain.

Management Comments

• "Our Board believes that the election of the director nominees identified herein, the Auditor Proposal, the Issuance Proposal, the Inducement Proposal, the Reverse Split Proposal, and the Adjournment Proposal are advisable and in the best interests of the Company and its stockholders and recommends that you vote FOR each of the two director nominees and FOR Proposals 2, 3, 4, 5, and 6."
• "We believe that the Private Placement, which yielded net proceeds of approximately $2.3 million, was necessary in light of our cash and funding requirements at the time."
• "Our Board strongly believes that the Reverse Stock Split is necessary to maintain our listing on Nasdaq."
• "Gerald T. Proehl, as one of our founders and as our President, Chief Executive Officer and Chairman, has extensive knowledge of all aspects of us, our business and the risks associated with our business."
• "Mr. Proehl voluntarily agreed to a base salary of $280,000, which the Compensation Committee approved, in an effort to preserve the Company's cash."

Industry Context

Dermata Therapeutics operates in the biotechnology and pharmaceutical industries, which are highly capital-intensive. The company's current situation, marked by a low stock price and the need for a reverse stock split to maintain Nasdaq listing, is a common challenge faced by smaller-cap biotech firms that rely heavily on capital raises to fund their research and development or operational needs. The significant dilution from recent warrant issuances reflects the difficulty in securing non-dilutive funding in this sector, especially for companies facing compliance issues.

Corporate Governance

Related Party Transactions

• Sean Proehl, son of CEO Gerald T. Proehl, is employed as Associate General Counsel with an annual salary of $212,000.
• Gerald T. Proehl (through Proehl Investment Ventures LLC) purchased 787,402 shares and accompanying warrants for $1,000,000.54 in the January 2025 Private Placement.
• Mary Fisher (Director) purchased 196,851 shares and accompanying warrants for $250,000.77 in the January 2025 Private Placement.
• Other related persons, including CFO Kyri K. Van Hoose, Director David F. Hale, and Sean Proehl, also participated in the January 2025 Private Placement for amounts less than $120,000.
• The company has entered into indemnification agreements with current directors and executive officers, requiring indemnification to the fullest extent permitted under Delaware law and advancement of expenses.
• The Board has adopted a written related person transaction policy for review and approval of transactions exceeding $120,000 or 1% of average total assets.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the issuance of shares underlying warrants. Will experience a reduction in the number of shares owned post-reverse stock split, though proportionate ownership will remain the same (excluding fractional share payouts). Risk of further dilution from future capital raises. Potential for increased stock price and liquidity if Nasdaq listing is maintained, but also risk of continued price decline and reduced liquidity.
• **Employees/Management**: Executive officers and directors have had previous stock options cancelled for no consideration, though new options were granted. Management's compensation includes base salary and performance-based bonuses. The CEO voluntarily reduced his salary to preserve cash.
• **Creditors/Investors**: The capital raises provide immediate funding, which could improve the company's financial stability in the short term, but the ongoing need for capital and the low stock price indicate financial vulnerability.

Next Steps

• Hold the Annual Meeting of Stockholders on July 15, 2025, to vote on the proposed matters.
• If approved, the Board will determine the exact ratio for the reverse stock split (between 1:2 and 1:30) and implement it prior to July 15, 2026.
• The company will continue to seek stockholder approval for warrant issuances every 90 days if not obtained at the initial meeting, until approval is secured or warrants are no longer outstanding.
• The company will publish final voting results in a Current Report on Form 8-K within four business days of the Annual Meeting.
• The company will continue to require additional capital in the near future to fund operations, potentially leading to further equity issuances.

Key Dates

Recommendation

Keywords

Dermata Therapeutics, Reverse Stock Split, Nasdaq Delisting, SEC Filing, Proxy Statement, Capital Raise, Warrants, Biotechnology, Pharmaceuticals, Corporate Governance, Shareholder Meeting, DRMA